Nuvation Bio (NUVB) was a big mover last session on higher-than-average trading volume. The latest t

Nuvation Bio reports positive long-term Phase 2 safusidenib data for glioma patients and expands its

U.S. stocks saw mixed results, with Nasdaq up 150 points. AMC shares rose after beating earnings exp

Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progressi

Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progressi

RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and lowe

Truist Securities analyst Gregory Renza maintains Nuvation Bio (NYSE:NUVB) with a Buy and raises

U.S. stock futures up, Nasdaq 100 futures gain 2%. H.B. Fuller shares dip 8.3% on earnings release a

Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tacklin

Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest ch

RBC Capital analyst Leonid Timashev reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and mai

Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and main

HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and m

Nuvation Bio (NYSE:NUVB) reported quarterly earnings of $0.01 per share which met the analyst consen

Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest ch

Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and main

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest c

Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and main

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), a human-centered global le

Clinical data demonstrate IBTROZI's unprecedented durability in TKI-naïve advanced ROS1-positive

UBS analyst Michael Yee maintains Nuvation Bio (NYSE:NUVB) with a Neutral and lowers the price ta

RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and rais

MDB stock fell 27.2% in pre-market trading after reporting Q4 earnings of $1.65 per share, revenue o

Shares of Ouster Inc (NASDAQ:OUST) rose sharply in pre-market trading after the company reported bet

Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.11) per share which missed the analyst con

Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and main

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest c

RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and rais

HC Wainwright & Co. analyst Robert Burns maintains Nuvation Bio (NYSE:NUVB) with a Buy and lo

Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest ch

Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., "Nuv

Strategic collaboration expands taletrectinib global reach with a leading oncology partnerEisai will

UBS analyst Michael Yee initiates coverage on Nuvation Bio (NYSE:NUVB) with a Neutral rating and

HC Wainwright & Co. analyst Robert Burns maintains Nuvation Bio (NYSE:NUVB) with a Buy and ra

Safusidenib demonstrated durable responses, with an ORR of 44% and 88% of patients were progression-

HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and m

On November 26, 2025, the Company announced its decision to discontinue development of NUV-1511, the

Truist Securities analyst Gregory Renza initiates coverage on Nuvation Bio (NYSE:NUVB) with a Buy

Citizens analyst Silvan Tuerkcan maintains Nuvation Bio (NYSE:NUVB) with a Market Outperform and

B. Riley Securities analyst Mayank Mamtani initiates coverage on Nuvation Bio (NYSE:NUVB) with a